Latest Health News

Wesfarmers has reported a 9.3% rise in net profit after tax to $1.6 billion for H1 2026, driven by robust performances in Bunnings, Kmart Group, and lithium operations. The company also announced a 7.4% increase in its interim dividend amid ongoing cost pressures and strategic AI partnerships.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Infragreen Group Limited reports a remarkable turnaround with a statutory net profit of A$3.64 million for H1 2025 and declares its inaugural interim dividend, underscoring confidence in its sustainable infrastructure investments.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Judo Capital Holdings Limited has announced a quarterly distribution of AUD 1.825 per capital note, fully franked and payable on 18 May 2026. The payment reflects a calculated yield based on prevailing market rates and remains subject to company discretion.

Adherium Limited has raised $6.7 million through a Placement and Institutional Entitlement Offer, positioning itself to expand its digital respiratory management solutions and advance value-based care contracts with US insurers.

Chariot Resources Ltd has voluntarily suspended trading on the ASX as it finalises a significant financing arrangement, with an announcement expected by 20 February 2026.

Santos Limited’s 2025 Annual Report reveals a robust operational and financial performance, highlighted by a 42% reduction in Scope 1 and 2 emissions and progress on major LNG projects Barossa and Pikka phase 1.

Lycopodium Limited reports strong half-year results for 1H FY26, driven by increased project delivery and strategic expansion into the Americas. The company updates its full-year guidance amid a robust pipeline across gold, copper, and critical minerals.

XRF Scientific has reported a record first half for December 2025, with revenue and profits rising on the back of strong mining demand and international expansion.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.